PTO Appeal Reverses on Idenix; Gilead Holds Cards in HIV Case
By Randy Osborne
Monday, March 25, 2013
Having taken one step forward, Idenix Pharmaceuticals Inc. got pushed one back when the U.S. Patent and Trademark Office (USPTO) appeals board flipped a decision made earlier that favored Idenix over Gilead Pharmaceuticals Inc. in an interference dispute over patents related to hepatitis C virus (HCV) drugs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.